Chong Kun Dang's Tamivir is listed as the lowest price

From March, Tamivir 3 Items, Industry's Interest in the Flu Pandemic

Chong Kun Dang, which has stopped selling the flu treatment "Tamiflu" since this year, was immediately covered by the salary of its generic drug.

 

Chong Kun Dang has been selling Tamiflu for more than a decade in partnership with Roche Korea since 2012 and has not released its own generics with only permission.

 

According to the industry on the 20th, Tamivir 30, 45, and 75mg per Chong Kun Dang will be listed as salary at 524, 907 won, and 1063 won, respectively.

 

Tamivir was approved in December 2009 and was the earliest Korean generic to be approved.

 

Chong Kun Dang has been unable to come to the market since 2012 because it has sold the original Tamiflu capsule in partnership with Roche Korea.

 

Instead, Chong Kun Dang has been selling suspension powder products that are not in the original under the Tamivir brand.

 

At the beginning of the year, Chong Kun Dang sent an official letter to the distribution industry and officially announced the suspension of Tamiflu sales, saying that the salesperson of 75, 45, and 30mg of Tamiflu capsules had been changed from Chong Kun Dang to Roche Korea as of January 6.

 

As a result, the registration of Tamivir is interpreted as a measure following the suspension of sales of Tamiflu by Chong Kun Dang.

 

The Tamivir capsule is currently the lowest price on the same system.

 

In the case of Oseltamivir capsule 30mg, the highest price is 854 won and the lowest price is 790 won, which is 266-330 won more expensive than Chong Kun Dang Tamivir products.

 

45 mg and 75 mg also differ in price from Chong Kun Dang products.

 

Analysts say that Chong Kun Dang is likely to settle in the market for a short period of time as it has experience in selling Tamiflu and has price competitiveness.

 

As COVID-19 subsides, the flu is on the rise again, and some predict that it could exceed the expected sales in March without supply issues.

 

Attention is focused on how much sales Chong Kun Dang, which changed its product from original to generic, will make in the market.